1. Home
  2. IMNN vs FBGL Comparison

IMNN vs FBGL Comparison

Compare IMNN & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNN
  • FBGL
  • Stock Information
  • Founded
  • IMNN 1982
  • FBGL 1996
  • Country
  • IMNN United States
  • FBGL Singapore
  • Employees
  • IMNN N/A
  • FBGL N/A
  • Industry
  • IMNN Biotechnology: Pharmaceutical Preparations
  • FBGL Miscellaneous manufacturing industries
  • Sector
  • IMNN Health Care
  • FBGL Consumer Discretionary
  • Exchange
  • IMNN Nasdaq
  • FBGL Nasdaq
  • Market Cap
  • IMNN 12.9M
  • FBGL 10.5M
  • IPO Year
  • IMNN 1985
  • FBGL 2025
  • Fundamental
  • Price
  • IMNN $3.77
  • FBGL $0.65
  • Analyst Decision
  • IMNN Buy
  • FBGL
  • Analyst Count
  • IMNN 2
  • FBGL 0
  • Target Price
  • IMNN $182.61
  • FBGL N/A
  • AVG Volume (30 Days)
  • IMNN 56.4K
  • FBGL 357.1K
  • Earning Date
  • IMNN 11-13-2025
  • FBGL 05-15-2026
  • Dividend Yield
  • IMNN N/A
  • FBGL N/A
  • EPS Growth
  • IMNN N/A
  • FBGL N/A
  • EPS
  • IMNN N/A
  • FBGL N/A
  • Revenue
  • IMNN N/A
  • FBGL $10,491,303.00
  • Revenue This Year
  • IMNN N/A
  • FBGL N/A
  • Revenue Next Year
  • IMNN N/A
  • FBGL N/A
  • P/E Ratio
  • IMNN N/A
  • FBGL N/A
  • Revenue Growth
  • IMNN N/A
  • FBGL N/A
  • 52 Week Low
  • IMNN $3.56
  • FBGL $0.41
  • 52 Week High
  • IMNN $41.22
  • FBGL $5.45
  • Technical
  • Relative Strength Index (RSI)
  • IMNN 35.44
  • FBGL 58.21
  • Support Level
  • IMNN $3.56
  • FBGL $0.56
  • Resistance Level
  • IMNN $4.38
  • FBGL $0.65
  • Average True Range (ATR)
  • IMNN 0.30
  • FBGL 0.07
  • MACD
  • IMNN 0.00
  • FBGL 0.01
  • Stochastic Oscillator
  • IMNN 21.95
  • FBGL 76.64

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

Share on Social Networks: